Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tolvaptan (Otsuka).

Sheila A Doggrell1

  • 1Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.co.nz

Current Opinion in Investigational Drugs (London, England : 2000)
|October 27, 2004
PubMed
Summary

Otsuka is developing tolvaptan, a vasopressin V2 antagonist, as a potential diuretic treatment for congestive heart failure. This novel drug was in phase III clinical trials as of November 2003.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same author

Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?

Expert opinion on pharmacotherapy·2026
Same author

Is seltorexant, an orexin-2 receptor antagonist, showing promise in insomnia?

Expert opinion on investigational drugs·2026
Same author

Does varenicline promote abstinence in youths who vape?

Expert opinion on pharmacotherapy·2025
Same author

Reply to: reframing guselkumab's benefit in ulcerative colitis: insights from QUASAR and emerging evidence.

Expert opinion on biological therapy·2025
Same author

With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?

Expert opinion on biological therapy·2025

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Congestive heart failure (CHF) is a complex syndrome characterized by fluid overload.
  • Diuretic therapy is a cornerstone in managing CHF, but current options have limitations.
  • Vasopressin plays a role in fluid balance and its antagonism is a potential therapeutic strategy.

Purpose of the Study:

  • To evaluate tolvaptan, an orally active non-peptide vasopressin V2 antagonist, for the treatment of congestive heart failure.
  • To assess the efficacy and safety of tolvaptan as a novel diuretic agent.

Main Methods:

  • Tolvaptan (OPC-41061) was developed as a selective vasopressin V2 receptor antagonist.
  • The drug was investigated in phase III clinical trials.
  • Pharmacological studies focused on its diuretic properties and effects on fluid balance.

Main Results:

  • Tolvaptan demonstrated potential as an orally active diuretic.
  • Its mechanism involves selective antagonism of vasopressin V2 receptors.
  • Clinical trials were underway to confirm efficacy in CHF patients.

Conclusions:

  • Tolvaptan represents a promising new therapeutic approach for managing fluid overload in congestive heart failure.
  • Further clinical evaluation was necessary to establish its role in standard CHF treatment protocols.

Related Experiment Videos